NO20060650L - Kinazolinderivater som angiogeneseinhibitorer - Google Patents
Kinazolinderivater som angiogeneseinhibitorerInfo
- Publication number
- NO20060650L NO20060650L NO20060650A NO20060650A NO20060650L NO 20060650 L NO20060650 L NO 20060650L NO 20060650 A NO20060650 A NO 20060650A NO 20060650 A NO20060650 A NO 20060650A NO 20060650 L NO20060650 L NO 20060650L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- aromatic
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229940121369 angiogenesis inhibitor Drugs 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000006168 tricyclic group Chemical group 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0318422.3A GB0318422D0 (en) | 2003-08-06 | 2003-08-06 | Chemical compounds |
| PCT/GB2004/003376 WO2005014582A1 (en) | 2003-08-06 | 2004-08-05 | Quinazoline derivatives as angiogenesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060650L true NO20060650L (no) | 2006-04-24 |
Family
ID=27839732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060650A NO20060650L (no) | 2003-08-06 | 2006-02-09 | Kinazolinderivater som angiogeneseinhibitorer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7989460B2 (enExample) |
| EP (1) | EP1658280A1 (enExample) |
| JP (1) | JP4890249B2 (enExample) |
| KR (1) | KR20060058705A (enExample) |
| CN (1) | CN1863794B (enExample) |
| AU (1) | AU2004263360A1 (enExample) |
| BR (1) | BRPI0413284A (enExample) |
| CA (1) | CA2534811A1 (enExample) |
| GB (1) | GB0318422D0 (enExample) |
| IL (1) | IL173484A0 (enExample) |
| MX (1) | MXPA06001395A (enExample) |
| NO (1) | NO20060650L (enExample) |
| WO (1) | WO2005014582A1 (enExample) |
| ZA (1) | ZA200601025B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| HN2002000067A (es) * | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | Inhibidores de la rho - quinasa. |
| EP2292615A1 (en) * | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Quinazoline compounds |
| MX2007004403A (es) | 2004-10-12 | 2007-04-27 | Astrazeneca Ab | Derivados de quinazolina. |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| CL2007003158A1 (es) * | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. |
| KR20100072266A (ko) * | 2007-10-24 | 2010-06-30 | 머크 샤프 앤드 돔 코포레이션 | 헤테로사이클 페닐 아미드 ｔ-형 칼슘 채널 길항제 |
| US8211911B2 (en) * | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
| US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
| US9353123B2 (en) * | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| USD746538S1 (en) * | 2014-02-03 | 2015-12-29 | Nautilus Hyosung Inc. | Automated teller machine |
| USD765340S1 (en) * | 2014-03-24 | 2016-08-30 | Nautilus Hyosung Inc. | Automated teller machine |
| USD746539S1 (en) * | 2014-03-24 | 2015-12-29 | Nautilus Hyosung Inc. | Automated teller machine |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| CN112996784B (zh) * | 2018-09-18 | 2023-05-30 | 北京越之康泰生物医药科技有限公司 | 吲哚衍生物及其在医药上的应用 |
| TW202300152A (zh) | 2021-03-10 | 2023-01-01 | 美商纜圖藥品公司 | Ｅｇｆｒ抑制劑 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| IL153805A0 (en) * | 2000-08-09 | 2003-07-31 | Astrazeneca Ab | Cinnoline compounds |
| WO2002030926A1 (en) * | 2000-10-13 | 2002-04-18 | Astrazeneca Ab | Quinazoline derivatives |
| US20040063733A1 (en) * | 2000-10-25 | 2004-04-01 | Lambert Christine Marie Paul | Quinazoline derivatives |
| ES2272737T3 (es) * | 2001-07-16 | 2007-05-01 | Astrazeneca Ab | Derivados de quinolina y su uso como inhibidores de tirosina quinasas. |
| AU2002347336A1 (en) * | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives |
| EP2292615A1 (en) | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Quinazoline compounds |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| CA2631764A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
-
2003
- 2003-08-06 GB GBGB0318422.3A patent/GB0318422D0/en not_active Ceased
-
2004
- 2004-08-05 EP EP04743664A patent/EP1658280A1/en not_active Withdrawn
- 2004-08-05 JP JP2006522400A patent/JP4890249B2/ja not_active Expired - Fee Related
- 2004-08-05 MX MXPA06001395A patent/MXPA06001395A/es unknown
- 2004-08-05 CA CA002534811A patent/CA2534811A1/en not_active Abandoned
- 2004-08-05 AU AU2004263360A patent/AU2004263360A1/en not_active Abandoned
- 2004-08-05 WO PCT/GB2004/003376 patent/WO2005014582A1/en not_active Ceased
- 2004-08-05 CN CN2004800290795A patent/CN1863794B/zh not_active Expired - Fee Related
- 2004-08-05 BR BRPI0413284-0A patent/BRPI0413284A/pt not_active IP Right Cessation
- 2004-08-05 US US10/566,842 patent/US7989460B2/en not_active Expired - Fee Related
- 2004-08-05 KR KR1020067002540A patent/KR20060058705A/ko not_active Withdrawn
-
2006
- 2006-01-31 IL IL173484A patent/IL173484A0/en unknown
- 2006-02-03 ZA ZA200601025A patent/ZA200601025B/en unknown
- 2006-02-09 NO NO20060650A patent/NO20060650L/no not_active Application Discontinuation
-
2011
- 2011-06-20 US US13/164,310 patent/US20120046300A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007501210A (ja) | 2007-01-25 |
| IL173484A0 (en) | 2006-06-11 |
| MXPA06001395A (es) | 2006-05-19 |
| US20080058342A1 (en) | 2008-03-06 |
| CN1863794B (zh) | 2012-04-25 |
| AU2004263360A1 (en) | 2005-02-17 |
| WO2005014582A1 (en) | 2005-02-17 |
| CA2534811A1 (en) | 2005-02-17 |
| EP1658280A1 (en) | 2006-05-24 |
| JP4890249B2 (ja) | 2012-03-07 |
| US20120046300A1 (en) | 2012-02-23 |
| CN1863794A (zh) | 2006-11-15 |
| GB0318422D0 (en) | 2003-09-10 |
| US7989460B2 (en) | 2011-08-02 |
| KR20060058705A (ko) | 2006-05-30 |
| BRPI0413284A (pt) | 2006-10-10 |
| ZA200601025B (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6622824B2 (ja) | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 | |
| CN108235704B (zh) | 抗细菌化合物 | |
| CN115151541B (zh) | 新型化合物及其用途 | |
| US9802951B2 (en) | Biologically active taxane analogs and methods of treatment by oral administration | |
| JP6963262B2 (ja) | 新規抗癌剤 | |
| JP5897566B2 (ja) | 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用 | |
| EP3027614A1 (de) | Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen | |
| EA200900388A1 (ru) | Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus | |
| MY144042A (en) | Quinazoline compounds | |
| WO2019005841A1 (en) | THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION | |
| IL207669A (en) | Nitrogen compounds containing nitrogen active in chronic pain states | |
| EP3880680A1 (en) | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin | |
| AU2014258419A2 (en) | Dicarboxylic acid compound | |
| WO2017197151A1 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| JP2013505254A (ja) | プロテインキナーゼ阻害のための新規化合物及びその治療的使用 | |
| KR20170037116A (ko) | 플루오로기가 치환된 프탈라지논 유도체 및 그 제조방법 | |
| NO20060641L (no) | Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser | |
| WO2008106125A3 (en) | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists | |
| BR9910628A (pt) | Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária | |
| WO2019129114A1 (zh) | 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 | |
| EP1732544A2 (en) | Treatment of tremor with histamine h3 inverse agonists or histamine h3 antagonists | |
| EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
| KR20150003749A (ko) | 세균성 질병 치료용 피리미딘 유도체 | |
| HK40067537A (en) | Antibacterial compounds | |
| KR20080014017A (ko) | (5ｚ)-5-(6-퀴녹살리닐메틸리덴)-2-[(2,6-디클로로페닐)아미노]-1,3-티아졸-4(5ｈ)-온 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |